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The aim of this paper is to compare the evolution of antidepressant consumption in France, Germany 
and the United Kingdom between 1998 and 2002. Commercial databases (IMS Health) have been 
used in conjunction with administrative data (PACT for the UK, GKV for Germany and Afssaps for 
France) to estimate antidepressant consumption in Daily Defined Doses. The main results are: (1) 
Antidepressant consumption has increased significantly over the last decade in France (x2), Germany 
(x2.4) and the UK (x3.8); (2) SSRIs are the most heavily consumed drugs in France (67%) and the UK 
(60%); (3) Germany is distinguished by an overall level of antidepressant consumption twice as low as 
the other two countries and a relatively low use of SSRI antidepressants (31%), in favour of TCAs. In 
conclusion, the combined use of administrative and commercial data is possible for an evaluation of 
the volume of consumption. This study sheds both medical and economic light on the differences in 
both the level and structure of consumption in these three countries.  
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According to the WHO, depression is the leading cause of Years Lost due to Disability
2 in Europe[1]. 
In all these countries, the rise in the consumption of antidepressants, and particularly selective 
serotonin reuptake inhibitors (SSRIs), raises both economic questions and public health problems[2-
10]. The fact that SSRIs have a better clinical tolerance than other antidepressants encouraged many 
doctors to widely prescribe them. The downside of such a behaviour is that it contributes to increasing 
unnecessary expenditures in situations where the clinical and economic benefits have not been 
established[11]. , In 2004, the Food and Drug Administration began issuing warnings about the risk of 
suicide or worsening depression in patients treated with SSRIs[12]. Moreover, questions have often 
been raised about their efficacy, the appropriateness of prescriptions in relation to the diagnosis and 
the duration of treatment [13-15]. 
 
A survey carried out in 1992 comparing France, the United Kingdom, Germany and Italy showed that 
France was by far the largest consumer of antidepressants[16]. The situation appeared to be the same 
in 1998, despite growing use of these drugs in the United Kingdom[7]. More recently, the ESEMeD 
2000 survey showed that the prevalence of the use of antidepressants remained higher in France, 6% 
over one year, than in the other European countries studied - Belgium, Germany, Spain, the 
Netherlands and Italy – where it only reached 3.5%[17]. This French pre-eminence can be considered 
within the broader context of the consumption of psychotropic drugs, which is also higher than that of 
other European countries[18-20].  
 
In Europe, some national surveys have highlighted the growing consumption of antidepressants. In 
France, data from the Agence française de sécurité sanitaire des produits de santé (Afssaps) show an 
increase of 58% in the number of antidepressant units sold to pharmacies between 1994 and 2004[21] 
and a doubling in the turnover linked to these products (+ 210%). Amar et al. note the multiplication by 
a factor of 6.7 of sales in Euros between 1980 and 2001[22]. In the United Kingdom, the number of 
prescriptions of antidepressants has considerably increased over the last decades[4,23], even 
doubling over the period from 1975-1998[6]. According to the authors of these studies, this increase, 
estimated to be + 732% between 1990 and 1995[24], is mainly due to the introduction of SSRIs on the 
market. In Germany between 1990-1998, global consumption of SSRIs and antidepressants also rose. 
 
However, this review of the literature also shows a lack of recent comparative data on antidepressant 
consumption in Europe. Differences in the indicators and methodologies between countries make it 
difficult to compare results from studies based on national data. To our knowledge, only one study 
covering antidepressants as a whole compares five European countries for the period 2000-2004. It 
shows high rates of consumption growth in Italy and Germany, though the overall level was only half 
the level of that in the United Kingdom or France, but this study provides no information on each 
therapeutic sub-classes[25]. The aim of our study is to compare antidepressant consumption as a 
whole and by therapeutic sub-class, together with changes in consumption, in three countries: 
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Germany, France and the United Kingdom. Using the Daily Defined Dose, we seek to explain the 






Comparing the overall antidepressant consumption in each of these three countries requires the use of 
data covering the widest possible population in each country, together with all the treatments 
prescribed to patients both in and out of hospital. 
 
Data for France meet these criteria. They consist of the annual sales recorded by the Afssaps and 
were transmitted to us free of charge.  Information comes from sales that pharmaceutical companies 
declare annually for tax purposes. These data cover all pharmaceutical preparations sold in France 
(excluding French overseas departments) between 1998 and 2002. They specify the number of 
packages sold, distinguishing between community and hospital, and are available for each 
antidepressant. 
 
For Germany and England, we used two types of data: commercial databases and publicly available 
administrative data. The commercial databases were acquired from IMS Health, a commercial 
company which collects drug utilisation data in many countries. The data we bought concern quarterly 
sales of SSRIs in Germany and the United Kingdom from the first quarter of 1998 to the last quarter of 
2002. For each type of packaging, these data give the number of packages sold to hospitals, primary 
care physicians, community pharmacists and pharmaceutical wholesalers.  
 
IMS Health data were used to compare the data from France as they are the most comparable data 
available. Unfortunately, the data we bought only cover SSRIs and we had to extrapolate our results to 
obtain comparable estimations for the whole antidepressant class. This extrapolation was done using 
the data published by GKV and PACT, which cover all antidepressants, but in limited populations. 
 
For Germany, we used the annual data on reimbursement drawn up by the Gesetzliche Krankenkasse 
(GKV), the national health insurance scheme from 1998 to 2002. These data are published in an 
annual report called ‘Arzneiverordnungs-Report’[26] and are specified by substance in Daily Defined 
Doses
3 (DDD) for each antidepressant, including imports. The GKV covers about 90% of the German 
population and only covers drugs prescribed to outpatients.  
 
For England, we used the annual prescription data of the Prescribing Analysis and Cost Tabulation 
(PACT) published on-line by the Prescription Pricing Authority of the National Health Service for the 
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period from 1998 to 2002; these data come from prescriptions delivered by community pharmacists 
and appliance contractors, dispensing doctors and prescriptions submitted by prescribing doctors for 
items personally administered in England (http://www.dh.gov.uk/en/Publicationsandstatistics/ 
consulted on 22 October 2007). The data do not cover drugs dispensed in hospital or private 
prescriptions. Only the public data for England, which represents 84 % of the UK population, enable 
the number of DDD to be calculated for each antidepressant. We obtained the data for Scotland, 
calculated in DDD, from the site of the Scottish Minister of Health for the same period
4. For Northern 
Ireland and Wales, the data do not allow calculation of consumption in DDD and has not been 
included in this study (table 1). 
 
<<Insert table 1>> 
 
In detail, for Germany and the UK, we first calculated in DDD the share of SSRIs in the whole class of 
antidepressants, on the basis of GKV or PACT data, respectively. We then extrapolated the number of 
DDDs for SSRIs obtained in the IMS Health data from this share. In doing so, we estimated the 
number of DDDs for a whole class of antidepressants for each country. The results were expressed in 
DDD/1000 inhabitants/year. The number of inhabitants in each country was drawn up from OECD 
Health Data (http://www.ecosante.fr/)..  
 
The classification used follows the Anatomical Therapeutic Chemical (ATC) classification system of 
the WHO (http://www.whocc.no/atcddd/, consulted on 22 October 2007). Drugs belonging to the class 
of antidepressants (N06A) in 2002 were studied. For our purposes, three drug sub-classes were 
derived from the five items provided by the ATC classification (table 2):  
•  non-selective monoamine reuptake inhibitors, also called tricyclic antidepressants or TCAs 
(ATC class N06AA);  
•  selective serotonin reuptake inhibitors, or SSRIs (ATC class N06AB);  
•    ‘other antidepressants’, which groups together the ATC class of monoamine oxydase 
inhibitors (MAOIs) (ATC classes N06AF and N06AG) and other antidepressants (N06AX). 
 
<<Insert table 2>> 
 
In order to take into account the existing differences between doses and packaging across countries, 
sold quantities of antidepressants (number of packages) have been expressed in DDD. DDD is 
established by a committee of experts (Nordic Council on Medicines) on the basis of the main 
therapeutic use of the main active ingredient [27]. Note that calculations based on WHO standards 
have been carried out when the DDD was not available. 
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Results 
 
In 2002, the number of DDD/1000 inhabitants/year of antidepressants was estimated to be 18,479 for 
the United Kingdom, 16,490 for France and 8,188 for Germany. From 1998 to 2002, the consumption 
of antidepressants showed constant growth in all three countries, but it increased most in Germany, 
where consumption rose by a factor of 1.7, followed by the United Kingdom with a factor of 1.5 and 
France with a factor of 1.3 (table 3). Over ten years, on the contrary, growth appeared higher in the 
United Kingdom (x3.8) than in the other two countries (x2.4 for Germany and x2 for France). 
 
<<Insert table 31>> 
 
In 2002, the number of DDD/1000 inhabitants/year for SSRIs was 11,115 per 1000 inhabitants in 
France and 11,012 per 1000 inhabitants in the United Kingdom. In Germany, this figure was only 
2,565 per 1000 inhabitants, i.e. four times less. Both in France and the United Kingdom, SSRIs 
represented two-thirds of the units consumed (France, 67%; UK, 60%). The remaining third was 
distributed differently in each country. In France, TCAs constituted 12% of DDDs and other 
antidepressants 21%, whereas in the United Kingdom, these molecules represented 27% and 13% of 
DDDs, respectively. In Germany, SSRIs only represented 31% of DDDs  and TCAs were the most 
widely used molecules, with 50% of DDDs. The structure of consumption is therefore totally different 
between Germany and the other two countries (figure 1). 
 
<< Insert figure 1 >> 
 
The evolution of the structure of antidepressant consumption has been the same in all three countries; 
we have seen an increase in the proportion of treatments with SSRIs and  ‘other antidepressants’, 
combined with a substantial fall in the use of TCAs. Despite the low consumption of SSRIs in 
Germany, this was the country in which their share increased most between 1998 and 2002 (+ 68% 
compared to 13% in France and 11% in the UK).  
 
Within the sub-class of TCAs, amitryptiline remained the most commonly consumed antidepressant in 
all 3 countries in 2002 (46% of DDDs for TCAs in England, 41% in France and 34% in Germany). The 
second-most used substance varied from one country to another: clomipramine with 32% of DDDs for 
TCAs in France, dosulepine in England (26%) and doxepine in Germany (22%). According to the Rote 
Liste® of 2006
 (http://www.rote-liste.de, consulted on 22 October 2007), doxepine, very seldom used 
in France and the United Kingdom, appears to benefit from wider indications for use in Germany than 
in the other two countries (for example, for sleeping disorders, whereas in France and the United 
Kingdom, in 2006, it was only indicated for severe depressive episodes.  
 - 6 - 
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Among the SSRIs, German doctors clearly preferred sertraline, with 41% of DDDs for SSRIs, followed 
by paroxetine (27%) and fluoxetine (19%). French and English doctors preferred fluoxetine and 




The two major findings of the present study are the huge increase in the consumption of 
antidepressants over the last decade in France, Germany and the United Kingdom and the differences 
in the consumption patterns between Germany and the other countries. Consumption reached 
comparable levels in France and the UK whether in terms of overall antidepressant or in terms of 
SSRIs. SSRIs were the most consumed antidepressants in France and in the United Kingdom, 
followed by  ‘other antidepressants’ in France and by TCAs in the United Kingdom. Germany was 
more atypical with an overall level of antidepressant consumption that was twice as low and a 
relatively low use of SSRI antidepressants, in favour of TCAs.  
 
The level of antidepressant consumption depends on the prevalence of depression in each country, 
the prevalence of diagnosed depressions and the frequency of drug treatments within the context of 
other treatments, especially psychotherapy. Several factors help explain the low consumption in 
Germany. First, there is a low prevalence of severe depression as evaluated by the modified Mini-
International Neuropsychiatric Interview (MINI): 4% over 6 months in 1995[28] (according to the same 
source, the prevalence of severe depressions is estimated to be 9% in France and 10% in the United 
Kingdom). Second, these depressions are often poorly diagnosed[29] because of the low utilisation of 
the health care system by patients suffering from depression – only 23%[28]. Treatments are also 
under-used, with only 35% of severe depression receiving drug treatment[30]. This under-use is 
particularly noticeable in the elderly: more than 9 out of 10 depressed elderly patients in Germany are 
not treated, especially in institutions[31]. Finally, Gandjour et al. observe a high rate of treatments that 
are inappropriate in terms of duration and/or dose: 65% of patients suffering from severe depression 
receive inadequate treatment in Germany, compared with 47% in the United Kingdom; in Germany, 
43% of treatments for severe depression are of inappropriate duration (30% in England), 9% involve 
an unsuitable dose (13% in England) and 13% combine both factors (4% in England) [15]. 
 
In line with a recent study, we found that the low level of antidepressant consumption in Germany is 
partly offset by high consumption of herbal medicines[32]. Consumption of plants with antidepressant 
properties, for example St John’s wort or Kava-Kava, represent 70% of the consumption of SSRIs and 
20% of the whole class of antidepressants in our data for 2002. The consumption of herbal medicines 
has, however, decreased considerably over the last few years.  
 
On the contrary, France,  is characterised by a higher prevalence of depression, 9% of severe 
depression over 6 months in 1995[16] and more frequent treatment with drugs: 51% of diagnosed 
severe depression is treated with drugs[30]. In 1998, a report by the Afssaps observed that the - 7 - 
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duration of treatment was too long with regard to current recommendations [33]. More recently, 
Lecadet et al. showed that the increase in antidepressant consumption is connected to an extension in 
the duration of treatments[34] and several authors have pointed out elsewhere the inappropriate use 
of antidepressants. Thus, SSRIs are prescribed in 22% of cases in the absence of psychiatric 
pathology and 32% of patients interrupt their treatment prematurely[14]. Furthermore, several studies 
point out the high frequency of off-label prescriptions: Kuhn et al. show that one-third of new SSRI 
treatments are off-label and Olié et al. record off-label prescriptions for 46% of patients taking 
antidepressants[35]. 
Finally, in the United Kingdom, in 1995, the prevalence of severe depression over 6 months was 
higher than in France, at 10%[28], but, as in Germany, only 35% of diagnosed severe depressions are 
treated with drugs[30]. The frequency of inappropriate treatments for severe depression, although 
lower than that observed in Germany, still reaches 47%: 30% are of inappropriate duration, 13% of 
unsuitable dose and 4% combine both factors[15].  
 
The differences observed in each country between the different classes of antidepressants may be the 
result either of national recommendations and reservations or of economic constraints. Germany is 
characterised by a low rate of SSRI use, despite current recommendations (1997), which consider 
them to be as effective as TCAs or moclobemide (MAOIs) as first-line treatments. However, German 
studies stressed haemorrhagic complications linked to SSRIs[36,37] and the German licensing 
authority, the Bundesgesundheitamt
5, expressed a number of reservations about the high number of 
suicides under fluoxetine, delaying authorisation for the German market for two years (The Guardian, 
30/10/1999). The cost of SSRIs did not appear to have an impact on their use, first because co-
payment in Germany was a contribution based solely on the size of the packaging and not on the price 
of the drug and, secondly, because the price of almost all antidepressants was below the reference 
price and therefore completely reimbursed (except the co-payment). However, it should be noted that 
German doctors are subject to prescription budgets which tend to direct their choice towards the least 
expensive drugs.  
 
In France, the recommendations of 1996 do not express a preference for any particular substance, but 
the criteria of choice specify that tolerance should be taken into account; the revised 
recommendations, published in 2002, clearly define the substances that should be prescribed as first-
line treatments: SSRIs and ‘other antidepressants’.  Unlike Germany, French recommendations 
underlined the good tolerance of SSRIs and doctors are not subject to any budget constraints, which 
may help explain the high proportion of SSRIs consumed. Finally, current English recommendations 
(drawn up in 2000) include SSRIs among the substances to be used for first-line treatment.  
 
SSRIs have seen the strongest rise in consumption within all classes of antidepressants in the three 
countries. This growth can be partly explained by their greater tolerance compared with the older 
antidepressants, TCAs and MAOIs. The numerous extensions to the indications for use from which 
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they have benefited since their introduction on the market in 1984 have also contributed to this growth: 
obsessive compulsive disorders, panic disorder, general or social anxiety disorders, bulimia nervosa 
and post-traumatic stress disorders. 
 
Over the last ten years, antidepressant consumption has more than doubled in the United Kingdom, 
where a major national information campaign, ‘The Defeat Depression Campaign’  was conducted 
between 1992 and 1996 by the Royal College of Psychiatrists and the Royal College of General 
Practitioners. This campaign was aimed at both health professionals, to improve the accuracy of their 
diagnoses, and patients, to de-stigmatise depression and encourage them to seek treatment [38]. An 
overall increase of 33% in the number of antidepressant prescriptions by GPs, 134% for SSRIs and 
12% for TCAs, was observed after this campaign [39]. This was followed, from 1998 to 2003, by 
another campaign: the ‘Changing Minds Campaign’ 
(http://www.rcpsych.ac.uk/campaigns/changingminds.aspx consulted on 22 October 2007).  
 
Methodological discussion  
 
The first limitation in our study lies in the use of data sources whose comparability may be debatable. 
Using the SSRIs data from IMS Health that we obtained for Germany and the United Kingdom, we 
verified that the volume of SSRI consumption was similar to national administrative sources (PACT 
data for the UK and GKV data for Germany). In both cases, the IMS Health data give a higher volume 
of consumption in DDD, by 10% for the United Kingdom and 17% for Germany (figure 2).  
 
<<Insert figure 2>> 
 
In the two countries, the lower figure obtained from administrative data is essentially due to the lack of 
hospital data in the PACT and GKV data, although they are included in the IMS Health data (see table 
1). The missing population in both the PACT data (8 %) and the GKV data (10%) could also affect the 
SSRI consumption level, if this population did not have the same pattern of consumption. In Germany, 
for example, the exclusion of people with high incomes, not affiliated to the GKV, may lead to an 
overestimation in the GKV data, linked to the lower consumption of people from a higher 
socioeconomic class[40]; however, this factor does not call into question the large difference observed 
between the two countries. 
 
The German and British data also appear to be comparable to those in France. The IMS Health data 
measure wholesaler sales and direct sales to pharmacies, whereas the Afssaps data are based on 
pharmaceutical companies’ sales on the domestic market; stocks held by wholesalers are the only 
possible cause of divergence. Moreover, with the exception of IMS Health UK data, which only cover 
97% of the market, the German IMS data [41], like those of the Affsaps in France, are exhaustive.  
 - 9 - 
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The extrapolation of the number of DDDs for SSRIs obtained from the IMS Health data, based on the 
structure of consumption observed in the PACT or GKV data, is subject to several hypotheses and 
constitutes the second limitation to this study. Firstly, it assumes that the share of SSRIs consumed in 
hospitals is the same as that sold in pharmacies. In the French data, the share is, in fact, slightly lower 
in hospitals, but over the years this gap has tended to narrow (3% in 2003). In addition, for Germany, 
we assume that people not affiliated to the GKV (10%) have the same pattern of consumption by class 
of antidepressants as those who are affiliated. We have tested the impact on our extrapolation of two 
reverse hypotheses: that the non-affiliated 10% have a higher or lower consumption. Even under the 
hypothesis that they consume twice as much as those affiliated to the GKV, the extrapolation results in 
a rise of 10% in total antidepressant consumption, meaning that consumption in Germany is still far 
lower than that in the United Kingdom and France. Finally, for the United Kingdom, the implicit 
hypothesis in our calculation is that the structure of antidepressant consumption in DDD in Wales and 
Northern Ireland is the same as that observed in the rest of the UK. The data for each county of the 
UK are only available as net ingredient cost and show a quite similar cost structure in each country, 
suggesting that the structure in terms of the number of DDDs is also relatively similar
6 (table 4).  
 
<<Insert table 4>> 
 
Lastly, the third methodological limitation lies in the use of DDD to measure consumption. Although it 
makes it possible to overcome the problem of differences in packaging and doses in different 
countries, the DDD is no more than a standard measure relating to the main indication of the product. 
As a consequence, it fails to take the prescribed daily dose (PDD) into account. A study of lipid-
lowering drugs has shown that, depending on the drug, the PDD can differ very markedly from the 
DDD, and that the PDD varies strongly from one country to another[42]. Similar divergences are 
possible for antidepressants. In addition, Donoghue has shown that for some antidepressant 




Our results not only concur with those obtained in a certain number of national studies, they above all 
shed light on antidepressant consumption differences in space (France, Germany and the United 
Kingdom) and time (1992-2002). This study underlines a clear increase in the number of DDDs for 
antidepressants, and particularly for SSRIs, over a specific period. Contrary to data from 1992, France 
now shares the highest level of antidepressant use with the United Kingdom, while Germany remains 
at a distinctly lower level of consumption. Our study also highlights the substantial use of SSRIs in 
France and the UK, whereas Germany still favours TCAs. For these three countries, the combined use 
of administrative and commercial data is possible for an evaluation of the volume of consumption. 
Future studies should examine other European countries and refine the measurement of consumption 
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by means of average prescribed doses; they should also include the use of psychotherapy as a 
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a
 For Northern Ireland and Wales, PACT data are only available at an aggregate level and only for a few years; they do not 
allow for the calculation of DDD. 
 
Table 2: Antidepressant substances available in the British, French and German markets in 2002. 
 
TCAs (N06AA)  France Germany UK
amineptine          
amitriprtylline x  x  x 
amitriptylinoxid     x    
amoxapine x      x 
clomipramine x  x  x 
desipramine  x       
dibenzepin     x    
dosulepine (dothiepin)  x     x 
doxepine x  x  x 
imipramine x  x  x 
lofepramine hydrochloride       x 
maprotiline x  x  x 
nortriptyllin     x  x 
opipramol     x    
protriptyline hydrochloride         
quinupramine          
timipramine x  x  x 
           
SSRIs (N06AB)  France Germany UK
citalopram x  x  x 
escitalopram x      x 
fluoxetin x  x  x 
fluvoxamin x      x 
paroxetin x  x  x 
paroxetine mésilate  x       
sertralin x  x  x 
      
Other antidepressants  France Germany UK
N06AF          
iproniazide  x       
Isocarboxazid        x 
nialamide          
phenelzine sulphate        x 
tranylcypromin     x  x 
N06AG          
moclobémide x  x  x 
toloxatone  x       
N06AX          
medifoxamine          
mianserine x  x  x 
milnacipran  x       
minaprine          
mirtazapine x  x  x 
nefazodon        x 
oxaflozane          
reboxetin     x  x 
tianeptine  x       
trazadone     x  x 
tryptophan        x 
venlafaxine x  x  x 
viloxazine  x       
      
 - 15 - 
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Table 3: Number of DDD per 1000 inhabitants and per year for antidepressants in Germany, 
France and the United Kingdom 
DDD per 1000 inhabitants per 
year Germany  United  Kingdom  France 
1992 [16]  3 406    4 816    8 145   
…          
1998  4 681    12 059  12 495   
1999  5 253    13 364  13 769   
2000  5 891    14 884  14 398   
2001  6 769    17 203  15 437   
2002  8 188    18 479  16 490   
Evolution 2002/1992  2.4% 3.8%  2.0% 
Evolution 2002/1998  1.7% 1.5%  1.3% 
 
Table 4: Share of SSRIs in total antidepressant consumption in Net Ingredient Cost, 
per country of the United Kingdom 
  England & Scotland  Wales  N. Ireland  UK total 
Percentage of the population 92.3%  4.9%  2.8%  100% 
Share of SSRIs in total antidepressant consumption in Net Ingredient Cost 
2000  68.34% 66.24%  66.77%  68.15% 
2001  66.36% 65.80%  61.95%  66.14%   




Figure 1:  Number of DDDs per 1000 inhabitants and per year by class of antidepressants in 
Germany, France and the United Kingdom 
 
 
Figure 2 : Number of DDDs per 1000 inhabitants per year for SSRIs according to different 
sources of data available in France, the United Kingdom and Germany from 1998 to 2002. - 16 - 
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Evolution 1998-2002 of the antidepressant consumption in France, Germany 
and the United Kingdom
Nathalie Grandfils (Irdes), Catherine Sermet (Irdes)
The  aim  of  this  paper  is  to  compare  the  evolution  of  antidepressant  consumption  in  France,  Germany  and  the 
United Kingdom between 1998 and 2002. Commercial databases (IMS Health) have been used in conjunction with 
administrative data (PACT for the UK, GKV for Germany and Afssaps for France) to estimate antidepressant consumption 
in Daily Defined Doses. The main results are: (1) Antidepressant consumption has increased significantly over the 
last decade in France (x2), Germany (x2.4) and the UK (x3.8); (2) SSRIs are the most heavily consumed drugs in France 
(67%) and the UK (60%); (3) Germany is distinguished by an overall level of antidepressant consumption twice as low 
as the other two countries and a relatively low use of SSRI antidepressants (31%), in favour of TCAs. In conclusion, the 
combined use of administrative and commercial data is possible for an evaluation of the volume of consumption. 
This study sheds both medical and economic light on the differences in both the level and structure of consumption 
in these three countries.
Evolution 1998-2002 de la consommation d’antidépresseurs en France, Allemagne 
et Royaume-Uni
Nathalie Grandfils (Irdes), Catherine Sermet (Irdes)
Cet article compare l’évolution de la consommation d’antidépresseurs en France, Allemagne et Royaume-Uni entre 
1998 et 2002.  Nous avons utilisé conjointement des sources de données administratives (données de PACT pour le 
RU, de la GKV pour l’Allemagne et de l’Afssaps pour la France) et des bases de données commerciales (IMS Health) pour 
estimer la consommation d’antidépresseurs en dose quotidienne définie (daily defined dose ou DDD). Les principaux 
résultats sont :  (1) une augmentation notable de la consommation au cours de la dernière décennie en France (x2), en 
Allemagne (x2.4) et au Royaume-Uni (x3.8) ; (2) les molécules les plus consommées en France (67%) et au Royaume Uni   
(60%) sont les inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) ; (3)l’Allemagne se distingue par un niveau de 
consommation global d’antidépresseurs deux fois plus bas et par une utilisation relativement faible des ISRS  au pro-
fit des tricycliques. En conclusion, sur ces trois pays, l’utilisation conjointe de données administratives et de données 
commerciales est possible pour une évaluation de la consommation en volume. Ce travail apporte un éclairage à la 
fois médical et économique sur les différences de consommation constatées entre ces trois pays, en niveau comme en 
structure. 